![Kenneth Mulvany](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Kenneth Mulvany
Directeur/Membre du Conseil chez BENEVOLENTAI
Postes actifs de Kenneth Mulvany
Sociétés | Poste | Début | Fin |
---|---|---|---|
BENEVOLENTAI | Directeur/Membre du Conseil | 02/05/2024 | - |
BenevolentAI Bio Ltd.
![]() BenevolentAI Bio Ltd. Packaged SoftwareTechnology Services Part of BenevolentAI SA, BenevolentAI Bio Ltd. is a clinical-stage AI-enabled drug discovery and British development company founded in 2013. The company is based in London, UK. BenevolentAI Bio uses AI to augment scientific ingenuity in the drug discovery process, from target identification to clinical development, with the goal of improving the probability of clinical success. The company has refined and formalized its approach to sustainability under the direction of the newly established environmental, social, and governance (ESG) governance structure and teams. BenevolentAI Bio's AI-enabled Benevolent Platform™ empowers scientists to uncover new insights from data, helping to accelerate innovation and increase the probability of discovering a successful drug. | Directeur/Membre du Conseil | 13/11/2013 | - |
The Cure Parkinson's Trust | Directeur/Membre du Conseil | - | - |
Historique de carrière de Kenneth Mulvany
Anciens postes connus de Kenneth Mulvany
Sociétés | Poste | Début | Fin |
---|---|---|---|
BENEVOLENTAI | Directeur/Membre du Conseil | 01/11/2013 | 30/06/2022 |
Fondateur | 01/11/2013 | 30/06/2022 | |
Minster Pharmaceuticals Plc
![]() Minster Pharmaceuticals Plc Pharmaceuticals: MajorHealth Technology Minster Pharmaceuticals Plc develops pharmaceutical compounds for the treatment of neurological and psychiatric conditions. The company operates in Tonabersat and Sabcomeline segments. The Tonabersat segment is for the prevention and treatment of migraine. The Sabcomeline segment is for the management of cognitive decline and negative symptoms in schizophrenia. Minster Pharmaceuticals was founded by Robert Stubbs and Paul Sharpe in 2001 and is headquartered in London, the United Kingdom. | Directeur/Membre du Conseil | 18/02/2010 | - |
BenevolentAI Ltd.
![]() BenevolentAI Ltd. Packaged SoftwareTechnology Services Part of BenevolentAI SA, BenevolentAI Ltd. develops artificial intelligence applications. The company is based in London, UK. The British company was founded in 2015 by Kenneth Patrick Mulvany, Ivan Griffin, Michael Brennan. BenevolentAI was acquired by Odyssey Acquisition SA on April 22, 2022 for $1,087.33 million. | Directeur/Membre du Conseil | 09/07/2021 | - |
Président | 17/09/2015 | 09/07/2021 | |
Fondateur | 17/09/2015 | - | |
Proximagen Group Plc
![]() Proximagen Group Plc Miscellaneous Commercial ServicesCommercial Services Proximagen Group Plc engages in the business of discovery and development of therapeutic treatments. The company was founded by Jenner Peter on November 2003 and is headquartered in Cambridge, the United Kingdom. | Directeur/Membre du Conseil | 09/11/2010 | - |
Directeur Général | 14/04/2005 | - | |
Fondateur | 14/04/2005 | - | |
Investor Relations Contact | 14/04/2005 | - |
Statistiques
Internationale
Royaume-Uni | 7 |
Opérationnelle
Director/Board Member | 7 |
Founder | 3 |
Chief Executive Officer | 1 |
Sectorielle
Technology Services | 3 |
Health Technology | 3 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
BENEVOLENTAI | Health Technology |
Entreprise privées | 5 |
---|---|
Proximagen Group Plc
![]() Proximagen Group Plc Miscellaneous Commercial ServicesCommercial Services Proximagen Group Plc engages in the business of discovery and development of therapeutic treatments. The company was founded by Jenner Peter on November 2003 and is headquartered in Cambridge, the United Kingdom. | Commercial Services |
Minster Pharmaceuticals Plc
![]() Minster Pharmaceuticals Plc Pharmaceuticals: MajorHealth Technology Minster Pharmaceuticals Plc develops pharmaceutical compounds for the treatment of neurological and psychiatric conditions. The company operates in Tonabersat and Sabcomeline segments. The Tonabersat segment is for the prevention and treatment of migraine. The Sabcomeline segment is for the management of cognitive decline and negative symptoms in schizophrenia. Minster Pharmaceuticals was founded by Robert Stubbs and Paul Sharpe in 2001 and is headquartered in London, the United Kingdom. | Health Technology |
BenevolentAI Ltd.
![]() BenevolentAI Ltd. Packaged SoftwareTechnology Services Part of BenevolentAI SA, BenevolentAI Ltd. develops artificial intelligence applications. The company is based in London, UK. The British company was founded in 2015 by Kenneth Patrick Mulvany, Ivan Griffin, Michael Brennan. BenevolentAI was acquired by Odyssey Acquisition SA on April 22, 2022 for $1,087.33 million. | Technology Services |
BenevolentAI Bio Ltd.
![]() BenevolentAI Bio Ltd. Packaged SoftwareTechnology Services Part of BenevolentAI SA, BenevolentAI Bio Ltd. is a clinical-stage AI-enabled drug discovery and British development company founded in 2013. The company is based in London, UK. BenevolentAI Bio uses AI to augment scientific ingenuity in the drug discovery process, from target identification to clinical development, with the goal of improving the probability of clinical success. The company has refined and formalized its approach to sustainability under the direction of the newly established environmental, social, and governance (ESG) governance structure and teams. BenevolentAI Bio's AI-enabled Benevolent Platform™ empowers scientists to uncover new insights from data, helping to accelerate innovation and increase the probability of discovering a successful drug. | Technology Services |
The Cure Parkinson's Trust |
- Bourse
- Insiders
- Kenneth Mulvany
- Expérience